TITLE

Bevacizumab plus interferon better for renal cell carcinoma

AUTHOR(S)
Shafer, Emily; Dreicer, Robert
PUB. DATE
April 2008
SOURCE
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p7
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the ability of interferon-alpha plus bevacizumab combination in improving the progression-free survival and response rate in metastatic renal cell carcinoma compared with interferon-alpha alone, based on a study. The study randomly subjected the patients with previously untreated metastatic clear-cell renal cell carcinoma to interferon-alpha with or without bevacizumab. The results show that the combination treatment has better median time to progression.
ACCESSION #
31705842

 

Related Articles

  • Bevacizumab + INF-α-2a: safer and therefore less costly in mRCC.  // PharmacoEconomics & Outcomes News;11/27/2010, Issue 617, p2 

    The article offers information on studies in Portugal and Mexico, which revealed that the use of bevacizumab in combination with interferon-α-2a (INF-α-2a) is well tolerated and could be a cheaper alternative to sunitinib for metastatic renal cell carcinoma (mRCC) treatment.

  • Bevacizumab + INF-α-2a: safer and therefore less costly in mRCC.  // Reactions Weekly;11/27/2010, Issue 1329, p1 

    The article discusses two research which found that bevacizumab combined with interferon-α-2a are safer and more cost-effective in treating metastatic renal cell carcinoma (mRCC).

  • CALGB 90206: Bevacizumab plus interferon improved PFS in metastatic RCC.  // Hem/Onc Today;6/25/2009, Vol. 10 Issue 12, p14 

    The article reports on the findings of a study conducted by Brian Rini and colleagues regarding the role of bevacizumab and interferon in improving progression-free survival (PFS) in metastatic renal cell carcinoma, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting...

  • Genentech/Roche/Chugai: Avastin gets FDA go-ahead for kidney cancer.  // PharmaWatch: Monthly Review;Sep2009, Vol. 8 Issue 9, p8 

    The article reports on the approval of Avastin plus interferon alpha by the U.S. Food & Drug Administration (FDA) for the first-line metastatic renal cell carcinoma (RCC) treatment. It states that the approval is based on the result of the Phase III AVOREN trial. It notes that Avastin have been...

  • Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Castellano, D.; Del Muro, X. Garcia; Pérez-Gracia, J. L.; González-Larriba, J. L.; Abrio, M. V.; Ruiz, M. A.; Pardo, A.; Guzmán, C.; Cerezo, S. Díaz; Grande, E. // Annals of Oncology;Nov2009, Vol. 20 Issue 11, p1803 

    Background: The purpose of this study is to evaluate the impact on the health-related quality of life (HRQoL) of sunitinib versus interferon-alpha (IFN-α) treatment in patients with metastatic renal cell carcinoma (mRCC).

  • Optimal treatment for metastatic renal cell cancer.  // Contemporary Urology;Mar2002, Vol. 14 Issue 3, p60 

    Discusses research being done on treatment for metastatic renal cell cancer. Reference to a study by Ian F. Tannock et al, published in the "New England Journal of Medicine"; Median survival of patients who underwent surgery followed by interferon; Benefit of surgical removal of a primary tumor...

  • Bevcizumab Plus Interferon Alfa 2a for Metastatic Renal Carcinoma. Ershler, William B. // Clinical Oncology Alert;Feb2008, Vol. 24 Issue 2, p11 

    RENAL CELL CARCINOMA IS REFRACTORY TO STANdard chemotherapeutic approaches and survival for those with metastatic disease is limited. Approximately one-third of patients present with metastatic disease and almost another third will relapse with metastatic disease after initial curativeintent...

  • RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ravaud, A.; Barrios, C. H.; Alekseev, B.; Tay, M.-H.; Agarwala, S. S.; Yalcin, S.; Lin, C.-C.; Roman, L.; Shkolnik, M.; Anak, O.; Gogov, S.; Pelov, D.; Louveau, A.-L.; Melichar, B. // Annals of Oncology;Jul2015, Vol. 26 Issue 7, p1378 

    Background: The open-label, phase II RECORD-2 trial compared efficacy and safety of first-line everolimus plus bevacizumab (EVE/BEV) with interferon plus bevacizumab (IFN/BEV) in patients with metastatic renal cell carcinoma. Patients and methods: Previously untreated patients were randomized...

  • Targeted agents changing treatment of metastatic renal cell carcinoma.  // Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p1 

    The article focuses on the study of targeted molecular therapies such as bevacizumab, sunitinib and sorafenib as replacement for interferon-alpha in cases where metastatic clear cell renal cell carcinoma is treated with cytoreductive nephrectomy. Clinical data have reportedly shown the efficacy...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics